Maria Grazia Maratta

MD| Medical Oncologist | PhD Student, Fondazione Policlinico A. Gemelli - IRCCS @policlinicogemelli @unicatt |📚👩🏻‍⚕️| 📍Based in Rome

[Antonio Vitale @antoniovitaleMD]

Out in @FrontiersIn our experience in
combined treatment for oligometastatic gastric cancer! Thanks to @MGMaratta @CarmeloPozzo and other colleagues!

https://t.co/cTRkc1cTHq

[NET Cancer Day @netcancerday]

NETs are more common than you think. In prevalence they are more common than pancreatic cancer and patients with myeloma in the population.
☑️We help clinicians to keep NETs on their radar with #NETInfo in 11 languages: https://t.co/ekWhXLmXPv
#LetsTalkAboutNETs #MedTwitter

[NET Cancer Day @netcancerday]

Pancreatic NET is among the most common NETs. #Gastroenterologists can be misled by common gastric symptoms.
✅Let’s support doctors with a snapshot of 26 types of NETs in 11 languages: https://t.co/ekWhXLmpZX #LetsTalkAboutNETs #GITwitter #PancreasTwitter

[NET CONNECT powered by COR2ED @net_connectinfo]

A retrospective analysis on #PRRT for #NET reveals extending treatment beyond the standard 4 cycles may offer a safe & effective strategy. 📊 More cycles linked to better overall survival (72.8 months vs. 52.8 months) & disease-specific survival.

#MedEd

https://t.co/BrYNTWZ6Aj

[NET Cancer Day @netcancerday]

🦓Today is #NETCancerDay! Today we unite in one global voice to speak about neuroendocrine cancer and call for more NET awareness among HCPs, which will help them suspect it and diagnose it early.
📢Share our messages in 11 languages: https://t.co/9o0LqKBA9o #LetsTalkAboutNETs

[NET Cancer Day @netcancerday]

🦓Get ready: In 1 hour we start the ENETS-INCA #NETCancerDay Educational Webinar for patients and their families! Tune in from 12:00 to 14:15 CET on the ENETS website: https://t.co/5gBbZlO43n
#LetsTalkAboutNETs

[Carmelo Pozzo @CarmeloPozzo]

Gemelli Rome Oncology Team at #ESMO23 in Madrid #ESMO #Gemelli

[Maria Grazia Maratta @MGMaratta]

1st ASCO-AIOM clinical research course: glad to have been part of this!🩺💊🔬
Thanks to the faculty and to @AIOMtweet @ASCO
https://t.co/iYTm9U1JzK

[NET Cancer Day @netcancerday]

Neuroendocrine cancer is underrecognized. It often has very common symptoms and could be misdiagnosed as IBS, anxiety and asthma.
👉We need to place it on the diagnostic maps of HCPs.
✅Download #NETInfo in your language: https://t.co/5dFSpECBwv
#LetsTalkAboutNETs #GITwitter

[Maria Grazia Maratta @MGMaratta]

Three incredible days in #Vienna for the 20th Annual #ENETS23 Conference. Such a great opportunity for #NETworking and #research. United to reflect on the main strategies to improving #patientcare 👨🏼‍🔬👩🏻‍⚕️♥️🦓 @netcancerday @CureNETs #ENETS

[Lisa Yen @lisayentwin]

INCA/ENETS Symposium- @sugandhadureja shares an overview of the soon to be released“Think NENs” Educational Program for PCPs, available online in 5 languages. Engaging & educating PCPs is critical to improving diagnosis, treatment &access to care. @LACNETS @netcancerday @CureNETs

[Maria Grazia Maratta @MGMaratta]

🚨NOW ONLINE🚨our last work: #Radiomcs to predict #immunotherapy efficacy in advanced #renalcellcarcinoma: a retrospective study 📲💻👩🏻‍💻
https://t.co/4YWAg9XXzY

[ESMO - Eur. Oncology @myESMO]

Updated📢 Management of toxicities from #immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment & follow-up. W/ recommended assessment & tx algorithms according to grade of toxicity
https://t.co/e6v6jbs4OY
@HaanenJohn @wick_wolfgang @peters_solange @MarieKostine

[Yüksel Ürün @DrYukselUrun]

Cardiovascular complications of immune checkpoint inhibitors for cancer
#Oncocardiology #Cardiooncology
@escardio @myESMO @ASCO @OncoAlert @sitcancer @American_Heart
https://t.co/6A51as5z6h

[Maria Grazia Maratta @MGMaratta]

❗️Negative results from #CheckMate914 Trial 🫠🥲🤦🏻‍♀️
Possible reason….🤷🏻‍♀️❓
- Not all anti PD1 are the same? (Nivo < Pembro)
- M1 pts in KN564 vs only M0 in CM914?
🧐
Many other trials ongoing in #adjuvant #RCC… waiting for more data and more details!

[Toni Choueiri, MD @DrChoueiri]

JUST IN: adjuvant nivo+ipi (6 months) in high-risk RCC did not meet its primary endpoint of DFS. Press release by @bmsnews via @BusinessWire —Big News this am!

@OncoAlert

https://t.co/WtyFAMHQxl

[Andrea Corsello @AndreaCorsello]

Happy to share our review: Medullary Thyroid Cancer with Ectopic Cushing's Syndrome: A Case Report and Systematic Review of Detailed Cases from the Literature | Thyroid https://t.co/bfeW5bP4lX
@DianaEstherossi @thyroidjournal

🎯Key points summarized below

[Carlo M. Cicala @carlomcicala]

📣 in press: our review on #PARPi/ICI combo in #ovarian cancer 📣

will preclinical rationale and early clinical data translate into meaningful benefit? 4 trials results are awaited ⏰
@lucia_musacchio @FlorianaCamarda @ketta_lorusso @ESMO_Open @myESMO

https://t.co/fuuVS2fXiT

[Chiara Corti @CCortiMD]

There we are! So glad @myESMO managed to re-arrange this #meeting after cancellation due to #Covid-19 last December. Thank you all! @AlbigesL @ViktorGruenwald @crisuarez08 @tompowles1 @CPRT65 @MRoupret @y_loriot

[Laurence Albiges @AlbigesL]

@ViktorGruenwald kicking off @myESMO Preceptorship on Metastatic Urothelial Carcinoma and Kidney Cancer - Faculty @crisuarez08 @tompowles1 @CPRT65 @MRoupret @y_loriot, ABex, M Schmidinger, M De Santis, H Moch, G Von Amsberg line up for an intensive in person 2 days course !

[AIOM @AIOMtweet]

La campagna #dirittoalloblio non si ferma. Partecipa anche tu e firma per dire no alla discriminazione degli ex pazienti oncologici: https://t.co/Uov6GXf79A

#iononsonoilmiotumore #tunonseiltuotumore #fondazioneaiom #AIOM